TB-500
TB500; Ac-LKKTETQ; Acetylated thymosin beta-4 fragment 17–23
Source type: Identity study. Sources checked .
What the cited research examined
An analytical study identified an acetylated seven-amino-acid fragment in TB-500.
This fragment is not full-length thymosin beta-4. Findings for the full-length peptide cannot be transferred automatically.
Reference facts
- Half-life
- Not established for general human use by the cited source.
- Human dose range
- Not provided. This reference does not recommend a human dose.
- Administration interval
- Not established by these sources. A half-life is not a dosing schedule.
- Storage
- Product-specific information required. These sources do not establish a storage specification.
Safety context
Consult the separate FDA briefing for this specific fragment.
Research results and substance listings are not product approvals. The FDA overview distinguishes current Category 2 entries from withdrawn nominations; withdrawal does not establish safety.
Sources and review method
- TB-500 analytical identification study
- FDA TB-500 briefing (2026)
- FDA: bulk substances with potential safety risks (includes withdrawn nominations)
These are bounded summaries of the linked sources, not systematic reviews. An unknown field means that these sources do not establish a general-use value. It does not claim that no other literature exists.
The calculator converts values you provide. The planner organizes entries you choose. Neither tool assesses whether a substance or schedule is appropriate.